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INTRODUCTION AND OBJECTIVES: Active surveillance (AS)
is gaining increasing acceptance as an effective management strategy for men with low risk prostate cancer. We analyzed a regional prostate cancer collaborative in order to characterize variation in the utilization of AS among practitioners and identify factors influencing AS rates.
METHODS: The Pennsylvania Urologic Regional Collaborative (PURC), established in 2014, is a voluntary collaborative of urology practices in Southeastern Pennsylvania focused on the evaluation and improvement of prostate cancer care. We prospectively identified men with newly diagnosed prostate cancer across 6 academic and private practice sites from PURC, and determined the percentage of men initially managed with AS. Variations in AS rates by individual practitioner were determined for men with NCCN very low or low risk disease. Demographic and clinicopathologic parameters were assessed to determine how these factors influenced AS rates.
RESULTS: Between May 2015 and October 2016, 282 of 1154 (19.6%) men with newly diagnosed prostate cancer underwent AS as initial management strategy, including 82/104 (78.9%) men with NCCN very low and 133/322 (41.3%) with NCCN low risk disease. AS rates stratified by practitioner for men with very low or low risk disease ranged from 11.1% to 100% (Figure 1 ). Associations of demographic and clinicopathologic parameters with AS rates are shown in the Table. High PSA, Gleason score, clinical stage, and NCCN risk category were all strongly associated with decreased utilization of AS (all p-values < 0.01).
CONCLUSIONS: Recent data report AS rates as high as 91% and 74% for NCCN very low and low risk prostate cancer, respectively. In the PURC collaborative, we observed lower rates of AS utilization for men with low risk prostate cancer, and significant variation in AS utilization among practitioners. These findings demonstrate the potential importance of quality collaboratives such as PURC in helping to identify variations in care and targets for quality improvement within local markets. . 197, No. 4S, Supplement, Saturday, May 13, 2017 surveillance (AS). Yet, the ability to identify which patients are at risk for progression is limited to PSA-based biomarkers with variable utility. Multiparametric MRI (mpMRI) with fusion-guided prostate biopsy (FBx) has demonstrated utility in risk stratification for patients considering AS. We compared mpMRI characteristics with PSA kinetics for the prediction of pathologic progression in patients on AS. METHODS: A review of men on AS with serial mpMRI and 2 or more FBx sessions was performed. FBx sessions consisted of targeted biopsies and a 12-core systematic biopsy. Men who met NIH Expanded AS criteria included those with low and intermediate risk CaP, Gleason score ¼ 3+4 with no restriction on percent core involvement. Progression was defined by patients with initial Gleason 3+3 to any Gleason 4, and Gleason 3+4 to a primary Gleason 4 or higher. MRI progression was defined as increase in lesion suspicion score, size, or new lesion on follow-up. PSA density (PSAD) > 0.15ng/ml 2 , velocity (PSAV) > 0.75ng/ml/year, doubling time (PSAdt) < 3 years, and imaging characteristics were examined for association with pathologic progression at surveillance biopsy.
RESULTS: A total of 178 men were included for analysis. Median follow-up was 19 months . Median age, PSA, and prostate volume of our cohort were 63 years [IQR 58-68], 5.0ng/ml ] and 47.8ml .7] at enrollment. The sensitivity and specificity of predicting pathologic progression by mpMRI, PSAD, PSAV and PSAdt were 46% and 65%, 16% and 88%, 20% and 87%, and 30% and 75% respectively. A combination of MRI with PSAD, PSAV, or PSAdt yielded a sensitivity and specificity of 53% and 44%, 57% and 57%, or 63% and 49% respectively. Using a decision curve analysis, mpMRI offers a small additional benefit for predicting CaP progression.
CONCLUSIONS: MpMRI alone marginally outperforms PSA kinetics for predicting pathologic progression in men on AS for CaP. The combination of mpMRI with PSA parameters increases the sensitivity of identifying progression in AS patients, but still fails to capture a significant proportion of progression. Further research in prostate imaging and other biomarkers will be needed to more accurately risk stratify AS patients.
Source of Funding: This research was supported by the Intramural Research Program of the National Cancer Institute, NIH

MP43-18 FOR MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER, OLDER AGE AT DIAGNOSIS AND AT RADICAL PROSTATECTOMY PORTENDS POOR OUTCOMES
Sasha Druskin*, Mufaddal Mamawala, Jeffrey Tosoian, H. Ballentine Carter, Bruce Trock, Baltimore, MD INTRODUCTION AND OBJECTIVES: Compared to younger men with prostate cancer (PCa), older men with the disease are more likely to present at an advanced stage, and even when adjusting for stage and grade, to die of the disease. Despite this phenomenon, older men, often with competing comorbidities, are more likely to elect active surveillance (AS) rather than primary definitive treatment. We sought to investigate whether advanced age at PCa diagnosis is a risk factor for grade reclassification (GR) while on AS. Additionally, for men ultimately going on to have secondary radical prostatectomy (RP) after initial AS, we sought to investigate whether advanced age at RP is a risk factor for adverse post-operative outcomes, including pathologic Gleason score (GS) upgrading, adverse RP pathology, and biochemical recurrence (BCR).
METHODS: Between 1995 and 2016, 1554 men aged 41-81 years (median 66 years) with NCCN very low (70%) and low (30%) risk PCa on AS were followed using an institutional database. We queried this database to determine rates of GR (biopsy GS3+4), as well as pathologic GS upgrading, adverse RP pathology (pT3a or pathologic GS4+3), and BCR in patients going on to RP. A competing risk analysis was used to evaluate the association between age and time to GR and BCR. Likewise, a multivariable logistic regression model was used to determine whether age at RP was a significant risk factor for pathologic GS upgrading and adverse RP pathology. Odds (OR) and hazard (HR) ratios were calculated for 10-year age increases.
RESULTS: Of the 1554 men in our AS cohort, 331 (21%) had GR and 295 (19% of all men) went on to have RP. Of those who underwent RP, 155 (53%) had pathologic GS upgrading, 89 (30%) had adverse RP pathology, and 18 men (6%) developed BCR after a median of 3 years. Age at diagnosis of PCa was a significant risk factor for GR (HR 1.4; 95%CI 1.2-1.7; p¼0.0003). Of those going on to RP, age at RP was a significant risk factor for pathologic GS upgrading (OR 2.2; 95%CI 1.3-3.7; p¼0.005), adverse RP pathology (OR 2.6; 95%CI 1.4-4.9; p¼0.004), and BCR (HR 3.6; 95%CI 1.1-11.2; p¼0.03).
CONCLUSIONS: For men on AS, age at PCa diagnosis is a significant risk factor for GR, and age at RP after being on AS is a significant risk factor for pathologic GS upgrading, adverse RP pathology, and BCR. These observations have significant implications for monitoring older men on AS.
Source of Funding: None
MP43-19
INTRODUCTION AND OBJECTIVES: Active surveillance (AS) is a treatment option for favorable-risk prostate cancers (PCa). However, data concerning populations of African descent is missing. The objective of this study was to evaluate the safety and benefit of AS in an African Caribbean cohort with favorable-risk PCa.
METHODS: Between 2005 and 2016, a monocentric prospective cohort study was conducted in Guadeloupe (French West Indies), including patients with low-risk PCa (prostate-specific antigen [PSA] ¼10 ng/ml; Gleason ¼6) or favorable intermediate-risk PCa (PSA, 10-20 ng/ml; Gleason ¼7 (3+4); life expectancy <10 years) in AS. Treatment was recommended in case of histological progression, increase in Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e561
